glp 1 safe for pregnancy Maternal GLP-1 receptor activation inhibits fetal growth GLP-1 drugs and pregnancy: Who

Only 28.8% of participants exceeded 1 mg/week

These side effects often occur early on in treatment and tend to subside over time and rarely result in discontinuation of therapy

Tirzepatide carries a Boxed Warning regarding thyroid C-cell tumors observed in rodent studies and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Any compounded GLP-1 preparation under 503A must comply with applicable federal and state restrictions, including limits on compounding products that are essentially copies of commercially available FDA-approved drugs